Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Core Viewpoint - Vaxart, Inc. has appointed Kevin Finney to its Board of Directors, bringing extensive healthcare industry experience to support the company's strategic goals and milestones [1][3]. Group 1: Appointment Details - Kevin Finney's appointment is effective immediately, and he will serve on the Audit and Nominating and Governance Committees of the Board [2]. - The CEO of Vaxart, Steven Lo, expressed confidence that Finney's expertise will be a significant asset as the company advances its oral vaccine platform technology [3]. Group 2: Background of Kevin Finney - Finney has 35 years of leadership experience in the healthcare sector, currently serving as President and CEO of Autobahn Therapeutics since 2019 [1][5]. - His previous roles include President and COO of Abide Therapeutics, and he has held executive positions at Allergan, Prometheus Laboratories, and Amylin Pharmaceuticals [6][7]. Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines that can be stored and shipped without refrigeration [9]. - The company's current development programs include vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [9].